医学
西罗莫司
冠状动脉疾病
心脏病学
内科学
前瞻性队列研究
临床试验
外科
作者
Xiaozeng Wang,Haiwei Liu,Guosheng Fu,Bo Xu,Yujie Zhou,Xi Su,Huiliang Liu,Zheng Zhang,Bo Yu,Ling Tao,Qun Zheng,Lang Li,Kai Xu,Yaling Han
摘要
Abstract Objectives We aimed to evaluate the long‐term outcomes of the novel NeoVas sirolimus‐eluting bioresorbable scaffold (BRS) for the treatment of de novo coronary artery disease. Background The long‐term safety and efficacy of the novel NeoVas BRS are still needed to be elucidated. Methods A total of 1103 patients with de novo native coronary lesions for coronary stenting were enrolled. The primary endpoint of target lesion failure (TLF) was defined as a composite of cardiac death (CD), target vessel myocardial infarction (TV‐MI), or ischemia‐driven‐target lesion revascularization (ID‐TLR). Results A three‐year clinical follow‐up period was available for 1,091 (98.9%) patients. The cumulative TLF rate was 7.2% with 0.8% for CD, 2.6% for TV‐MI, and 5.1% for ID‐TLR. Additionally, 128 (11.8%) patient‐oriented composite endpoint and 11 definite/probable stent thromboses (1.0%) were recorded. Conclusions The extended outcomes of the NeoVas objective performance criterion trial demonstrated a promising 3‐year efficacy and safety of the NeoVas BRS in low‐risk patients with low complexity in terms of lesions and comorbidities.
科研通智能强力驱动
Strongly Powered by AbleSci AI